Korro Bio (KRRO) EBITDA Margin (2019 - 2025)
Korro Bio's (KRRO) quarterly EBITDA Margin came in at 3900.62% in Q4 2025, down 288609.0% on a YoY basis from N/an in Q4 2024, and down 121.02% quarter-over-quarter from 1764.86% in Q3 2025.
Powered by 
Analysis
Korro Bio (KRRO) EBITDA Margin (2019 - 2025) Analysis & Trends
Korro Bio (KRRO) has reported EBITDA Margin for 5 consecutive years, with 3900.62% the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin fell 288609.0% year-over-year to 3900.62%; the trailing twelve-month figure through Jun 2026 stood at 4625.48% (down 305640.0% YoY), and the FY2025 full-year result was 1906.37%, up 214075.0% from the prior year.
- EBITDA Margin declined to 3900.62% in Q4 2025 per KRRO's latest filing, from 1764.86% in the prior quarter.
- Across five years, EBITDA Margin topped out at 185.65% in Q2 2021 and bottomed at 3900.62% in Q4 2025.
- Historically, EBITDA Margin has averaged 1449.18% across 3 years, with a median of 1014.53% in 2024.
- The sharpest annual moves came in 2021 and 2025: EBITDA Margin sank 11291 bps in 2021, then slumped 288609 bps in 2025.
- Over 3 years, EBITDA Margin stood at 185.65% in 2021, then plunged by 446 bps to 1014.53% in 2024, then plunged by 284 bps to 3900.62% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 3900.62%, 1764.86%, and 1863.15% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Korro Bio | 231.15 Mn | 116.12 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -3,900.62% |
| Sep 30, 2025 | -1,764.86% |
| Jun 30, 2025 | -1,863.15% |
| Mar 31, 2025 | -981.18% |
| Dec 31, 2024 | -1,014.53% |
| Jun 30, 2021 | -185.65% |
| Mar 31, 2021 | -434.29% |
| Dec 31, 2020 | -103.29% |
| Sep 30, 2020 | -48.17% |
| Jun 30, 2020 | -72.74% |
| Mar 31, 2020 | -77.85% |
| Dec 31, 2019 | -137.78% |
| Sep 30, 2019 | -5.17% |